<DOC>
	<DOCNO>NCT02955394</DOCNO>
	<brief_summary>This randomize two arm phase II study evaluate efficacy fulvestrant plus enza compare single agent fulvestrant postmenopausal woman locally advance AR+/ER+/Her2- BC local surgery ~4 month treatment .</brief_summary>
	<brief_title>Preoperative Fulvestrant With Without Enzalutamide ER+/Her2- Breast Cancer</brief_title>
	<detailed_description>This randomize two arm phase II study evaluate efficacy fulvestrant plus enza compare single agent fulvestrant postmenopausal woman locally advance AR+/ER+/Her2- BC local surgery ~4 month treatment . After consent , patient get tissue biopsy , half patient get fulvestrant alone ( standard dosing ) half patient get fulvestrant plus enzalutamide . At ~4 week , biopsy do therapy continue . Hormone therapy continue ~4 month point patient undergo surgical resection .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>ER+ Her2 breast cancer Stage least T2 great Planned get local surgery Postmenopausal , pre peri menopausal , need concurrent ovarian suppression . At least 18 year age Not anticoagulants PS 02 Able swallow study drug comply study requirement ANC &gt; 1000/uL , platelet &gt; 75,000/uL screen visit Total bilirubin &lt; 1.5 time upper limit normal ( ULN ) screen visit unless alternate nonmalignant etiology exists ( eg , Gilbert 's disease ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 3 time ULN &lt; 5 time ULN patient document liver metastasis Creatinine &lt; 1.5 time ULN INR &lt; 1.5 time ULN , warfarin , safely transition biopsy Willing donate blood research 4 time point Willing undergo core biopsy research study entry ~4 week . Willing donate tissue research surgical specimen Written inform consent obtain prior biopsy blood sample Current previously treat brain leptomeningeal metastases History seizures Prior treatment antiandrogen ( abiraterone , ARN509 , bicalutamide , enzalutamide , ODM201 , TAK448 , TAK683 , TAK700 , VT464 ) . Systemic estrogen androgen within 14 day initiate therapy . Vaginal estrogen allow necessary patient comfort .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>101 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ER+/Her2 - breast cancer</keyword>
	<keyword>Preoperative Fulvestrant</keyword>
	<keyword>Enzalutamide</keyword>
</DOC>